BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

Doctors prescribe Briumvi (ublituximab-xiiy) for certain forms of multiple sclerosis (MS). You’ll receive infusions (into your vein) over a period of months. Before each infusion, you’ll receive other ...

Poster Presentation Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence ...

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ...

In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence ...

Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS treatment compared to their White peers, new research suggests. "The ...